Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
Nat Cancer ; 5(5): 742-759, 2024 May.
Article in English | MEDLINE | ID: mdl-38429414

ABSTRACT

Successful immunotherapy relies on triggering complex responses involving T cell dynamics in tumors and the periphery. Characterizing these responses remains challenging using static human single-cell atlases or mouse models. To address this, we developed a framework for in vivo tracking of tumor-specific CD8+ T cells over time and at single-cell resolution. Our tools facilitate the modeling of gene program dynamics in the tumor microenvironment (TME) and the tumor-draining lymph node (tdLN). Using this approach, we characterize two modes of anti-programmed cell death protein 1 (PD-1) activity, decoupling induced differentiation of tumor-specific activated precursor cells from conventional type 1 dendritic cell (cDC1)-dependent proliferation and recruitment to the TME. We demonstrate that combining anti-PD-1 therapy with anti-4-1BB agonist enhances the recruitment and proliferation of activated precursors, resulting in tumor control. These data suggest that effective response to anti-PD-1 therapy is dependent on sufficient influx of activated precursor CD8+ cells to the TME and highlight the importance of understanding system-level dynamics in optimizing immunotherapies.


Subject(s)
CD8-Positive T-Lymphocytes , Immunotherapy , Tumor Microenvironment , Animals , Mice , Immunotherapy/methods , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/drug effects , Tumor Microenvironment/immunology , Humans , Neoplasms/immunology , Neoplasms/therapy , Neoplasms/drug therapy , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Immune Checkpoint Inhibitors/pharmacology , Immune Checkpoint Inhibitors/therapeutic use , Dendritic Cells/immunology , Dendritic Cells/drug effects , Cell Line, Tumor
2.
Sci Immunol ; 8(81): eadd8005, 2023 03 10.
Article in English | MEDLINE | ID: mdl-36867679

ABSTRACT

FDA-approved anti-PD-L1 monoclonal antibodies (mAbs) bear the IgG1 isotype, whose scaffolds are either wild-type (e.g., avelumab) or Fc-mutated and lacking Fcγ receptor (FcγR) engagement (e.g., atezolizumab). It is unknown whether variation in the ability of the IgG1 Fc region to engage FcγRs renders mAbs with superior therapeutic activity. In this study, we used humanized FcγR mice to study the contribution of FcγR signaling to the antitumor activity of human anti-PD-L1 mAbs and to identify an optimal human IgG scaffold for PD-L1 mAbs. We observed similar antitumor efficacy and comparable tumor immune responses in mice treated with anti-PD-L1 mAbs with wild-type and Fc-mutated IgG scaffolds. However, in vivo antitumor activity of the wild-type anti-PD-L1 mAb avelumab was enhanced by combination treatment with an FcγRIIB-blocking antibody, which was co-administered to overcome the suppressor function of FcγRIIB in the tumor microenvironment (TME). We performed Fc glycoengineering to remove the fucose subunit from the Fc-attached glycan of avelumab to enhance its binding to the activating FcγRIIIA. Treatment with the Fc-afucosylated version of avelumab also enhanced antitumor activity and induced stronger antitumor immune responses compared with the parental IgG. The enhanced effect by afucosylated PD-L1 antibody was dependent on neutrophils and associated with decreased frequencies of PD-L1+ myeloid cells and increased infiltration of T cells in the TME. Our data reveal that the current design of FDA-approved anti-PD-L1 mAbs does not optimally harness FcγR pathways and suggest two strategies to enhance FcγR engagement to optimize anti-PD-L1 immunotherapy.


Subject(s)
Antibodies, Monoclonal , Receptors, IgG , Humans , Animals , Mice , Immunoglobulin G , Immune Checkpoint Inhibitors , Immunotherapy
3.
Nat Cancer ; 3(3): 287-302, 2022 03.
Article in English | MEDLINE | ID: mdl-35190724

ABSTRACT

Therapeutic use of agonistic anti-CD40 antibodies is a potentially powerful approach for activation of the immune response to eradicate tumors. However, the translation of this approach to clinical practice has been substantially restricted due to the severe dose-limiting toxicities observed in multiple clinical trials. Here, we demonstrate that conventional type 1 dendritic cells are essential for triggering antitumor immunity but not the toxicity of CD40 agonists, while macrophages, platelets and monocytes lead to toxic events. Therefore, we designed bispecific antibodies that target CD40 activation preferentially to dendritic cells, by coupling the CD40 agonist arm with CD11c-, DEC-205- or CLEC9A-targeting arms. These bispecific reagents demonstrate a superior safety profile compared to their parental CD40 monospecific antibody while triggering potent antitumor activity. We suggest such cell-selective bispecific agonistic antibodies as a drug platform to bypass the dose-limiting toxicities of anti-CD40, and of additional types of agonistic antibodies used for cancer immunotherapy.


Subject(s)
Antibodies, Bispecific , Neoplasms , Antibodies, Bispecific/pharmacology , CD40 Antigens , Dendritic Cells , Humans , Immunotherapy , Neoplasms/drug therapy
4.
Cell Rep ; 37(11): 110114, 2021 12 14.
Article in English | MEDLINE | ID: mdl-34883043

ABSTRACT

Messenger RNA-based vaccines against COVID-19 induce a robust anti-SARS-CoV-2 antibody response with potent viral neutralization activity. Antibody effector functions are determined by their constant region subclasses and by their glycosylation patterns, but their role in vaccine efficacy is unclear. Moreover, whether vaccination induces antibodies similar to those in patients with COVID-19 remains unknown. We analyze BNT162b2 vaccine-induced IgG subclass distribution and Fc glycosylation patterns and their potential to drive effector function via Fcγ receptors and complement pathways. We identify unique and dynamic pro-inflammatory Fc compositions that are distinct from those in patients with COVID-19 and convalescents. Vaccine-induced anti-Spike IgG is characterized by distinct Fab- and Fc-mediated functions between different age groups and in comparison to antibodies generated during natural viral infection. These data highlight the heterogeneity of Fc responses to SARS-CoV-2 infection and vaccination and suggest that they support long-lasting protection differently.


Subject(s)
COVID-19/immunology , Glycosylation/drug effects , SARS-CoV-2/immunology , Adult , Aged , Antibodies, Viral/immunology , BNT162 Vaccine/immunology , COVID-19 Vaccines/metabolism , Female , Humans , Immunoglobulin G/immunology , Immunoglobulin G/metabolism , Israel/epidemiology , Male , Middle Aged , Spike Glycoprotein, Coronavirus/immunology , Vaccination/methods , Vaccine Efficacy , Vaccines, Synthetic/immunology , Vaccines, Synthetic/metabolism , mRNA Vaccines/immunology , mRNA Vaccines/metabolism
5.
PLoS One ; 15(11): e0241164, 2020.
Article in English | MEDLINE | ID: mdl-33227020

ABSTRACT

The COVID-19 pandemic and the fast global spread of the disease resulted in unprecedented decline in world trade and travel. A critical priority is, therefore, to quickly develop serological diagnostic capacity and identify individuals with past exposure to SARS-CoV-2. In this study serum samples obtained from 309 persons infected by SARS-CoV-2 and 324 of healthy, uninfected individuals as well as serum from 7 COVID-19 patients with 4-7 samples each ranging between 1-92 days post first positive PCR were tested by an "in house" ELISA which detects IgM, IgA and IgG antibodies against the receptor binding domain (RBD) of SARS-CoV-2. Sensitivity of 47%, 80% and 88% and specificity of 100%, 98% and 98% in detection of IgM, IgA and IgG antibodies, respectively, were observed. IgG antibody levels against the RBD were demonstrated to be up regulated between 1-7 days after COVID-19 detection, earlier than both IgM and IgA antibodies. Study of the antibody kinetics of seven COVID 19 patients revealed that while IgG levels are high and maintained for at least 3 months, IgM and IgA levels decline after a 35-50 days following infection. Altogether, these results highlight the usefulness of the RBD based ELISA, which is both easy and cheap to prepare, to identify COVID-19 patients even at the acute phase. Most importantly our results demonstrate that measuring IgG levels alone is both sufficient and necessary to diagnose past exposure to SARS-CoV-2.


Subject(s)
Antibodies, Viral/immunology , COVID-19 Serological Testing/methods , COVID-19/diagnosis , COVID-19/epidemiology , Immunoglobulin G/immunology , Pandemics , Protein Domains/immunology , SARS-CoV-2/immunology , Adolescent , Adult , Aged , Aged, 80 and over , COVID-19/blood , COVID-19/virology , Cohort Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin A/blood , Immunoglobulin A/immunology , Immunoglobulin G/blood , Immunoglobulin M/blood , Immunoglobulin M/immunology , Male , Middle Aged , Reverse Transcriptase Polymerase Chain Reaction , SARS-CoV-2/genetics , Sensitivity and Specificity , Young Adult
6.
J Neuroimmunol ; 345: 577281, 2020 08 15.
Article in English | MEDLINE | ID: mdl-32534388

ABSTRACT

To identify the mechanisms relevant for the therapeutic effect of glatiramer acetate (GA), we studied T- and B- regulatory cells as well as GM-CSF expression in mice recovered from experimental autoimmune encephalomyelitis (EAE). Selective depletion of Tregs reduced but did not eliminate the ability of GA to ameliorate EAE, indicating a role for additional immune-subsets. The prevalence of Bregs in the periphery and the CNS of EAE-mice increased following GA-treatment. Furthermore, GA downregulated the pathological expression of GM-CSF, on both the protein and mRNA levels. These findings corroborate the broad immunomodulatory mechanism of action of GA in EAE/MS.


Subject(s)
B-Lymphocytes, Regulatory/metabolism , Glatiramer Acetate/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Immunosuppressive Agents/pharmacology , Multiple Sclerosis/metabolism , T-Lymphocytes, Regulatory/metabolism , Animals , B-Lymphocytes, Regulatory/drug effects , Disease Models, Animal , Female , Glatiramer Acetate/therapeutic use , Granulocyte-Macrophage Colony-Stimulating Factor/antagonists & inhibitors , Immunosuppressive Agents/therapeutic use , Mice , Mice, Inbred C57BL , Mice, Transgenic , Multiple Sclerosis/drug therapy , T-Lymphocytes, Regulatory/drug effects
7.
Cancer Immunol Immunother ; 68(8): 1287-1301, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31253998

ABSTRACT

Patchy infiltration of tumors by cytotoxic T cells (CTLs) predicts poorer prognosis for cancer patients. The factors limiting intratumoral CTL dissemination, though, are poorly understood. To study CTL dissemination in tumors, we histologically examined human melanoma samples and used mice to image B16-OVA tumors infiltrated by OT-I CTLs using intravital two-photon microscopy. In patients, most CTLs concentrated around peripheral blood vessels, especially in poorly infiltrated tumors. In mice, OT-I CTLs had to cluster around tumor cells to efficiently kill them in a contact-and perforin-dependent manner and cytotoxicity was strictly antigen-specific. OT-I CTLs as well as non-specific CTLs concentrated around peripheral vessels, and cleared the tumor cells around them. This was also the case when CTLs were injected directly into the tumors. CTLs crawled rapidly only in areas within 50 µm of flowing blood vessels and transient occlusion of vessels immediately, though reversibly, stopped their migration. In vitro, oxygen depletion and blockade of oxidative phosphorylation also reduced CTL motility. Taken together, these results suggest that hypoxia limits CTL migration away from blood vessels, providing immune-privileged niches for tumor cells to survive. Normalizing intratumoral vasculature may thus synergize with tumor immunotherapy.


Subject(s)
Blood Vessels/immunology , Lymphocytes, Tumor-Infiltrating/immunology , Melanoma/immunology , Skin Neoplasms/immunology , T-Lymphocytes, Cytotoxic/immunology , Animals , Antigens, Neoplasm/immunology , Cell Movement , Cytotoxicity, Immunologic , Humans , Melanoma/blood supply , Melanoma, Experimental , Mice , Mice, Inbred C57BL , Neoplasms, Experimental , Neovascularization, Pathologic , Oxidative Phosphorylation , Perforin/metabolism , Skin Neoplasms/blood supply
8.
Cancer Discov ; 8(11): 1366-1375, 2018 11.
Article in English | MEDLINE | ID: mdl-30209080

ABSTRACT

The quest for tumor-associated antigens (TAA) and neoantigens is a major focus of cancer immunotherapy. Here, we combine a neoantigen prediction pipeline and human leukocyte antigen (HLA) peptidomics to identify TAAs and neoantigens in 16 tumors derived from seven patients with melanoma and characterize their interactions with their tumor-infiltrating lymphocytes (TIL). Our investigation of the antigenic and T-cell landscapes encompassing the TAA and neoantigen signatures, their immune reactivity, and their corresponding T-cell identities provides the first comprehensive analysis of cancer cell T-cell cosignatures, allowing us to discover remarkable antigenic and TIL similarities between metastases from the same patient. Furthermore, we reveal that two neoantigen-specific clonotypes killed 90% of autologous melanoma cells, both in vitro and in vivo, showing that a limited set of neoantigen-specific T cells may play a central role in melanoma tumor rejection. Our findings indicate that combining HLA peptidomics with neoantigen predictions allows robust identification of targetable neoantigens, which could successfully guide personalized cancer immunotherapies.Significance: As neoantigen targeting is becoming more established as a powerful therapeutic approach, investigating these molecules has taken center stage. Here, we show that a limited set of neoantigen-specific T cells mediates tumor rejection, suggesting that identifying just a few antigens and their corresponding T-cell clones could guide personalized immunotherapy. Cancer Discov; 8(11); 1366-75. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333.


Subject(s)
Antigen Presentation/immunology , Antigens, Neoplasm/immunology , Histocompatibility Antigens Class I/immunology , Lymphocytes, Tumor-Infiltrating/immunology , Melanoma/immunology , T-Lymphocytes/immunology , Animals , Antigens, Neoplasm/metabolism , Histocompatibility Antigens Class I/metabolism , Humans , Melanoma/metabolism , Melanoma/pathology , Mice , Mice, Inbred NOD , Mice, SCID , T-Lymphocytes/metabolism , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
9.
Eur J Immunol ; 48(7): 1137-1152, 2018 07.
Article in English | MEDLINE | ID: mdl-29624673

ABSTRACT

The bone marrow hosts NK cells whose distribution, motility and response to systemic immune challenge are poorly understood. At steady state, two-photon microscopy of the bone marrow in Ncr1gfp/+ mice captured motile NK cells interacting with dendritic cells. NK cells expressed markers and effector molecules of mature cells. Following poly (I:C) injection, RNA-Seq of NK cells revealed three phases of transcription featuring immune response genes followed by posttranscriptional processes and proliferation. Functionally, poly (I:C) promoted upregulation of granzyme B, enhanced cytotoxicity in vitro and in vivo, and, in the same individual cells, triggered proliferation. Two-photon imaging revealed that the proportion of sinusoidal NK cells decreased, while at the same time parenchymal NK cells accelerated, swelled and divided within the bone marrow. MVA viremia induced similar responses. Our findings demonstrate that the bone marrow is patrolled by mature NK cells that rapidly proliferate in response to systemic viral challenge while maintaining their effector functions.


Subject(s)
Bone Marrow/immunology , Dendritic Cells/immunology , Killer Cells, Natural/immunology , Viremia/immunology , Animals , Antigens, Ly/genetics , Cell Differentiation , Cell Movement , Cell Proliferation , Cells, Cultured , Cytotoxicity, Immunologic , Granzymes/metabolism , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Mice, Transgenic , Natural Cytotoxicity Triggering Receptor 1/genetics , Poly I-C/immunology , Virus Activation
10.
Stem Cells Transl Med ; 7(1): 68-77, 2018 01.
Article in English | MEDLINE | ID: mdl-29266820

ABSTRACT

Repair of injured lungs represents a longstanding therapeutic challenge. We recently demonstrated that human and mouse embryonic lung tissue from the canalicular stage of development are enriched with lung progenitors, and that a single cell suspension of canalicular lungs can be used for transplantation, provided that lung progenitor niches in the recipient mice are vacated by strategies similar to those used in bone marrow transplantation. Considering the ethical limitations associated with the use of fetal cells, we investigated here whether adult lungs could offer an alternative source of lung progenitors for transplantation. We show that intravenous infusion of a single cell suspension of adult mouse lungs from GFP+ donors, following conditioning of recipient mice with naphthalene and subsequent sublethal irradiation, led to marked colonization of the recipient lungs, at 6-8 weeks post-transplant, with donor derived structures including epithelial, endothelial, and mesenchymal cells. Epithelial cells within these donor-derived colonies expressed markers of functionally distinct lung cell types, and lung function, which is significantly compromised in mice treated with naphthalene and radiation, was found to be corrected following transplantation. Dose response analysis suggests that the frequency of patch forming cells in adult lungs was about threefold lower compared to that found in E16 fetal lungs. However, as adult lungs are much larger, the total number of patch forming cells that can be collected from this source is significantly greater. Our study provides proof of concept for lung regeneration by adult lung cells after preconditioning to vacate the pulmonary niche. Stem Cells Translational Medicine 2018;7:68-77.


Subject(s)
Epithelial Cells/transplantation , Guided Tissue Regeneration/methods , Lung Injury/therapy , Lung/cytology , Stem Cell Transplantation , Stem Cells/cytology , Animals , Cells, Cultured , Epithelial Cells/cytology , Female , Lung/pathology , Mice , Mice, Inbred C57BL , Mice, Knockout , Naphthalenes/toxicity
11.
Eur J Immunol ; 47(10): 1802-1818, 2017 10.
Article in English | MEDLINE | ID: mdl-28872666

ABSTRACT

Antigen (Ag) specific activation of naïve T cells by migrating dendritic cells (DCs) is a highly efficient process, although the chances for their colocalization in lymph nodes (LNs) appear low. Ag presentation may be delegated from Ag-donor DCs to the abundant resident DCs, but the routes of Ag transfer and how it facilitates T-cell activation remain unclear. We visualized CD8+ T cell-DC interactions to study the sites, routes, and cells mediating Ag transfer in mice. In vitro, Ag transfer from isolated ovalbumin (OVA)+ bone marrow (BM) DCs triggered widespread arrest, Ca2+ flux, and CD69 upregulation in OT-I T cells contacting recipient DCs. Intravital two-photon imaging revealed that survival of Ag-donor DCs in LNs was required for Ag dissemination among resident CD11c+ DCs. Upon interaction with recipient DCs, CD8+ T cells clustered, upregulated CD69, proliferated and differentiated into effectors. Few DCs sufficed for activation, and for efficient Ag dissemination lymphocyte function associated antigen 1 (LFA-1) expression on recipient DCs was essential. Similar findings characterized DCs infected with a replication-deficient OVA-expressing Vaccinia virus known to downregulate MHC-I. Overall, active Ag dissemination from live incoming DCs helped activate CD8+ T cells by increasing the number of effective presenting cells and salvaged T-cell priming when Ag-donor DCs could not present Ag.


Subject(s)
Antigens/metabolism , CD8-Positive T-Lymphocytes/immunology , Cross-Priming , Dendritic Cells/immunology , Lymph Nodes/immunology , Animals , Antigen Presentation , Antigens/immunology , Antigens, CD/genetics , Antigens, CD/immunology , Antigens, Differentiation, T-Lymphocyte/genetics , Antigens, Differentiation, T-Lymphocyte/immunology , CD8-Positive T-Lymphocytes/metabolism , Cell Movement , Dendritic Cells/chemistry , Dendritic Cells/metabolism , Intravital Microscopy , Lectins, C-Type/genetics , Lectins, C-Type/immunology , Lymph Nodes/cytology , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Ovalbumin/genetics , Ovalbumin/immunology , Vaccinia virus/genetics , Vaccinia virus/physiology
12.
Cell Rep ; 20(11): 2547-2555, 2017 Sep 12.
Article in English | MEDLINE | ID: mdl-28903036

ABSTRACT

Cytotoxic T lymphocytes (CTLs) used in immunotherapy are typically cultured under atmospheric O2 pressure but encounter hypoxic conditions inside tumors. Activating CTLs under hypoxic conditions has been shown to improve their cytotoxicity in vitro, but the mechanism employed and the implications for immunotherapy remain unknown. We activated and cultured OT-I CD8 T cells at either 1% or 20% O2. Hypoxic CTLs survived, as well as normoxic ones, in vitro but killed OVA-expressing B16 melanoma cells more efficiently. Hypoxic CTLs contained similar numbers of cytolytic granules and released them as efficiently but packaged more granzyme-B in each granule without producing more perforin. We imaged CTL distribution and motility inside B16-OVA tumors using confocal and intravital 2-photon microscopy and observed no obvious differences. However, mice treated with hypoxic CTLs exhibited better tumor regression and survived longer. Thus, hypoxic CTLs may perform better in tumor immunotherapy because of higher intrinsic cytotoxicity rather than improved migration inside tumors.


Subject(s)
Antineoplastic Agents/metabolism , Cytotoxicity, Immunologic , Neoplasms/immunology , Neoplasms/pathology , T-Lymphocytes, Cytotoxic/immunology , Animals , Cell Differentiation , Cell Hypoxia/immunology , Cell Movement , Cell Proliferation , Cell Survival , Granzymes/metabolism , Mice , Neoplasms/blood supply , Survival Analysis
13.
Acta Neuropathol Commun ; 3: 1, 2015 Jan 15.
Article in English | MEDLINE | ID: mdl-25627031

ABSTRACT

INTRODUCTION: Anti-acetylcholine receptor (AChR) autoantibodies target muscles in spontaneous human myasthenia gravis (MG) and its induced experimental autoimmune model MG (EAMG). The aim of this study was to identify novel functional mechanisms occurring in the muscle pathology of myasthenia. RESULTS: A transcriptome analysis performed on muscle tissue from MG patients (compared with healthy controls) and from EAMG rats (compared with control rats) revealed a deregulation of genes associated with the Interleukin-6 (IL-6) and Insulin-Like Growth Factor 1 (IGF-1) pathways in both humans and rats. The expression of IL-6 and its receptor IL-6R transcripts was found to be altered in muscles of EAMG rats and mice compared with control animals. In muscle biopsies from MG patients, IL-6 protein level was higher than in control muscles. Using cultures of human muscle cells, we evaluated the effects of anti-AChR antibodies on IL-6 production and on the phosphorylation of Protein Kinase B (PKB/Akt). Most MG sera and some monoclonal anti-AChR antibodies induced a significant increase in IL-6 production by human muscle cells. Furthermore, Akt phosphorylation in response to insulin was decreased in the presence of monoclonal anti-AChR antibodies. CONCLUSIONS: Anti-AChR antibodies alter IL-6 production by muscle cells, suggesting a putative novel functional mechanism of action for the anti-AChR antibodies. IL-6 is a myokine with known effects on signaling pathways such as Akt/mTOR (mammalian Target of Rapamycin). Since Akt plays a key role in multiple cellular processes, the reduced phosphorylation of Akt by the anti-AChR antibodies may have a significant impact on the muscle fatigability observed in MG patients.


Subject(s)
Interleukin-6/metabolism , Muscle, Skeletal/metabolism , Myasthenia Gravis/pathology , Proto-Oncogene Proteins c-akt/metabolism , Adolescent , Adult , Animals , Antibodies/pharmacology , Cell Proliferation/drug effects , Cell Proliferation/genetics , Cells, Cultured , Child , Disease Models, Animal , Female , Freund's Adjuvant/toxicity , Gene Expression Profiling , Humans , Insulin-Like Growth Factor I/genetics , Insulin-Like Growth Factor I/metabolism , Interleukin-6/genetics , Male , Mice , Middle Aged , Myasthenia Gravis/etiology , Myasthenia Gravis/genetics , Myoblasts/drug effects , Myoblasts/metabolism , Phosphorylation , Rats , Rats, Inbred Lew , Receptors, Cholinergic/immunology , Receptors, Interleukin-6/metabolism , Young Adult
14.
Ann N Y Acad Sci ; 1274: 120-6, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23252906

ABSTRACT

Establishment of tolerance in myasthenia gravis (MG) involves regulatory T (T(reg)) cells. Experimental autoimmune MG (EAMG) in rats is a suitable model for assessing the contribution of T(reg) cells to the immunopathology of the disease and for testing novel T(reg) cell-based treatment modalities. We have studied two immunotherapeutic approaches for targeting of T(reg) cells in myasthenia. By one approach we demonstrated that treatment of sick rats by ex vivo-generated exogenous T(reg) cells derived from healthy donors suppressed EAMG. By a different approach, we aimed at affecting the endogenous T(reg)/Th17 cell balance by targeting IL-6, which has a key role in controlling the equilibrium between pathogenic Th17 and suppressive T(reg) cells. We found that treatment of myasthenic rats by neutralizing anti-IL-6 antibodies shifted this equilibrium in favor of T(reg) cells and led to suppression of EAMG. Our results show that T(reg) cells could serve as potential targets in treating MG patients.


Subject(s)
Immunotherapy/methods , Myasthenia Gravis, Autoimmune, Experimental/immunology , Myasthenia Gravis, Autoimmune, Experimental/therapy , T-Lymphocytes, Regulatory/metabolism , Animals , Antibodies, Neutralizing/therapeutic use , Humans , Immune Tolerance , Interleukin-6/immunology , Rats , T-Lymphocytes, Regulatory/transplantation , Th1 Cells/metabolism , Th17 Cells/metabolism
15.
Ann N Y Acad Sci ; 1275: 107-13, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23278585

ABSTRACT

Aire (autoimmune regulator) has a key role in the establishment of tolerance to autoantigens. Aire(-/-) mice present decreased thymic expression of AChR, significantly lower frequencies of regulatory T (T(reg)) cells, and higher expression of Th17 markers, compared to controls. We therefore predicted that Aire(-/-) mice would be more susceptible to induction of experimental autoimmune myasthenia gravis (EAMG). However, when EAMG was induced in young mice, Aire(-/-) mice presented a milder disease that wild-type (WT) controls. In contrast, when EAMG was induced in older mice, Aire(-/-) mice were more severely affected than WT mice. The relative resistance to EAMG in young Aire(-/-) mice correlated with increased numbers of T(reg) cells in their spleens compared to young controls. A similar age-related susceptibility was also observed when EAE was induced in Aire(-/-) mice, suggesting an age-related link among Aire, disease susceptibility, and peripheral T(reg) cells that may be a general feature of autoimmunity.


Subject(s)
Myasthenia Gravis/immunology , T-Lymphocytes, Regulatory/immunology , Transcription Factors/genetics , Aging , Animals , Genetic Predisposition to Disease , Mice , Mice, Knockout , AIRE Protein
16.
J Autoimmun ; 36(1): 16-24, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21035305

ABSTRACT

The autoimmune regulator (Aire) is involved in the prevention of autoimmunity by promoting thymic expression of tissue restricted antigens which leads to elimination of self-reactive T cells. We found that Aire knockout (KO) mice as well as mouse strains that are susceptible to experimental autoimmune myasthenia gravis (EAMG) have lower thymic expression of acetylcholine receptor (AChR- the main autoantigen in MG), compared to wild type (WT) mice and EAMG-resistant mouse strains, respectively. We demonstrated that Aire KO mice have a significant and reproducible lower frequency of CD4+Foxp3+ cells and a higher expression of Th17 markers in their thymus, compared to wild type (WT) mice. These findings led us to expect that Aire KO mice would display increased susceptibility to EAMG. Surprisingly, when EAMG was induced in young (2 month-old) mice, EAMG was milder in Aire KO than in WT mice for several weeks until the age of about 5 months. However, when EAMG was induced in relatively aged (6 month-old) mice, Aire KO mice presented higher disease severity than WT controls. This age-related change in susceptibility to EAMG correlated with an elevated proportion of Treg cells in the spleens of young but not old KO, compared to WT mice, suggesting a role for peripheral Treg cells in the course of disease. Our observations point to a possible link between Aire and Treg cells and suggest an involvement for both in the pathogenesis of myasthenia.


Subject(s)
Myasthenia Gravis, Autoimmune, Experimental/immunology , T-Lymphocytes, Regulatory/immunology , Thymus Gland/immunology , Transcription Factors/immunology , Age Factors , Animals , Cell Separation , Disease Susceptibility/immunology , Flow Cytometry , Fluorescent Antibody Technique , Mice , Mice, Inbred C57BL , Mice, Knockout , Receptors, Cholinergic/immunology , Receptors, Cholinergic/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Spleen/cytology , Spleen/immunology , Thymus Gland/cytology , Transcription Factors/deficiency , Transcription Factors/genetics , AIRE Protein
17.
J Neuroimmunol ; 220(1-2): 43-51, 2010 Mar 30.
Article in English | MEDLINE | ID: mdl-20100627

ABSTRACT

We have previously shown that several phosphodiesterase (PDE) subtypes are up-regulated in muscles and lymph node cells (LNC) of rats with experimental autoimmune myasthenia gravis (EAMG). In the present study we investigated PDE expression during the course of EAMG and experimental allergic encephalomyelitis (EAE) and found that the up-regulated expression of selected PDE subtypes in both experimental models is correlated with disease severity. In EAMG, PDE expression is correlated also with muscle damage. A similar up-regulation of PDE was also observed in the respective human diseases, MG and multiple sclerosis (MS). Our findings suggest that change in PDE expression levels is a general phenomenon in autoimmune diseases and may also be used as a marker for disease severity.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/enzymology , Multiple Sclerosis/enzymology , Myasthenia Gravis, Autoimmune, Experimental/enzymology , Myasthenia Gravis/enzymology , Phosphoric Diester Hydrolases/metabolism , Adolescent , Adult , Animals , Biomarkers/analysis , Biomarkers/blood , Child , Disease Models, Animal , Disease Progression , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/physiopathology , Female , Humans , Isoenzymes/metabolism , Multiple Sclerosis/immunology , Multiple Sclerosis/physiopathology , Muscular Atrophy/enzymology , Muscular Atrophy/immunology , Muscular Atrophy/physiopathology , Myasthenia Gravis/immunology , Myasthenia Gravis/physiopathology , Myasthenia Gravis, Autoimmune, Experimental/immunology , Myasthenia Gravis, Autoimmune, Experimental/physiopathology , Predictive Value of Tests , Rats , Rats, Inbred Lew , Severity of Illness Index , Up-Regulation/immunology , Young Adult
18.
J Neuroimmunol ; 209(1-2): 87-95, 2009 Apr 30.
Article in English | MEDLINE | ID: mdl-19232748

ABSTRACT

We have previously demonstrated that the chemokine IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3, are overexpressed in myasthenia gravis (MG) and its animal model experimental autoimmune MG (EAMG). We now studied the potential of modulating rat EAMG by interference in CXCR3/IP-10 signaling. Two different approaches were used: 1) blocking IP-10 by IP-10-specific antibodies and 2) inhibiting the CXCR3 chemokine receptor by a CXCR3 antagonist. Treatment by either of these reagents led to suppression of EAMG suggesting that inhibition of CXCR3/IP-10 signaling can be considered as a potential treatment modality for MG.


Subject(s)
Chemokine CXCL10/antagonists & inhibitors , Immunologic Factors/pharmacology , Immunotherapy/methods , Myasthenia Gravis, Autoimmune, Experimental/drug therapy , Myasthenia Gravis, Autoimmune, Experimental/immunology , Receptors, CXCR3/antagonists & inhibitors , Animals , Antibodies/pharmacology , Antibodies/therapeutic use , Chemokine CXCL10/genetics , Chemokine CXCL10/metabolism , Chemokines/drug effects , Chemokines/genetics , Chemokines/metabolism , Cytokines/drug effects , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Female , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Immunologic Factors/therapeutic use , Mice , Mice, Inbred BALB C , Myasthenia Gravis, Autoimmune, Experimental/physiopathology , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Rats , Rats, Inbred Lew , Receptors, CXCR3/genetics , Receptors, CXCR3/metabolism , Signal Transduction/drug effects , Signal Transduction/immunology
19.
J Neuroimmunol ; 201-202: 128-35, 2008 Sep 15.
Article in English | MEDLINE | ID: mdl-18632163

ABSTRACT

Myasthenia gravis (MG) is frequently treated by corticosteroids such as methylprednisolone. However, continuous treatment with steroids often results in adverse effects. In the present study we evaluated the therapeutic potential of a combination of suboptimal doses of methylprednisolone (Solumedrol) and Pentoxifylline (PTX), a general phosphodiesterase (PDE) inhibitor, in rat experimental autoimmune MG (EAMG). This combined treatment resulted in a pronounced suppressive effect on EAMG and was by far more effective than each of the drugs administered separately at these low doses. The suppressive effect on EAMG was accompanied by decreased humoral and cellular responses to AChR as well as down-regulated mRNA expression levels of Th1 cytokines and IL-10 in lymph node cells and of PDE-4 and cathepsin-l in the muscle. This study demonstrates the potential of PTX as a steroid-sparing agent in the management of myasthenia gravis.


Subject(s)
Glucocorticoids/therapeutic use , Methylprednisolone/therapeutic use , Myasthenia Gravis, Autoimmune, Experimental/drug therapy , Pentoxifylline/therapeutic use , Phosphodiesterase Inhibitors/therapeutic use , Animals , Antibodies/blood , Body Weight/drug effects , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Gene Expression Regulation/drug effects , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Myasthenia Gravis, Autoimmune, Experimental/blood , Myasthenia Gravis, Autoimmune, Experimental/pathology , Rats , Rats, Inbred Lew , Receptors, Cholinergic/immunology , Severity of Illness Index
20.
Ann N Y Acad Sci ; 1132: 244-8, 2008.
Article in English | MEDLINE | ID: mdl-18567875

ABSTRACT

Intravenous immunoglobulin (IVIG) administration has been beneficially used for the treatment of a variety of autoimmune diseases including myasthenia gravis (MG). We have demonstrated that IVIG administration in experimental autoimmune MG (EAMG) results in suppression of disease that is accompanied by decreased Th1 cell and B cell proliferation. Chromatography of pooled human immunoglobulins (IVIG) on immobilized IgG, isolated from rats with EAMG or from MG patients, results in a depletion of the suppressive activity of the IVIG. Moreover, reconstitution of the activity-depleted IVIG with the eluted minute IVIG fractions that had been adsorbed onto the EAMG- or MG-specific columns recovers the depleted immunosuppressive activity. This study supports the notion that the therapeutic effect of IVIG is mediated by an antigen-specific anti-immunoglobulin (anti-idiotypic) activity that is essential for its suppressive activity.


Subject(s)
Antibody Specificity/immunology , Immunoglobulins, Intravenous/immunology , Immunoglobulins, Intravenous/therapeutic use , Immunosuppressive Agents/immunology , Immunosuppressive Agents/therapeutic use , Myasthenia Gravis, Autoimmune, Experimental/immunology , Myasthenia Gravis, Autoimmune, Experimental/therapy , Animals , Humans , Immunotherapy , Rats , Receptors, Cholinergic/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...